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 ABSTRACT 
Spinal and Bulbar Muscular Atrophy (SBMA) or Kennedy's disease is an X-linked disease 
associated with the expansion of the CAG triplet repeat present in exon-1 on the androgen receptor 
(AR) gene. This results in the production of a mutant AR containing an elongated polyglutamine 
tract (polyQ) in its N-terminus. Interestingly, the ARpolyQ becomes toxic only after its activation 
by the natural androgenic ligands, possibly because of aberrant androgen-induced conformational 
changes of the ARpolyQ, which generate misfolded species. These misfolded ARpolyQ species 
must be cleared from motoneurons and muscle cells, and this process is mediated by the protein 
quality control (PQC) system. Experimental evidence suggested that failure of the PQC pathways 
occurs in disease, leading to ARpolyQ accumulation and toxicity in the target cells. In these review 
we summarized the overall impact of mutant and misfolded ARpolyQ on the PQC system and 
described how molecular chaperons and the degradative pathways (ubiquitin-proteasome system 
(UPS), the autophagy-lysosome pathway (ALP), and the unfolded protein response (UPR), which 
activates the endoplasmic reticulum-associated degradation (ERAD)) are differentially affected in 
SBMA. We also extensively and critically reviewed several molecular and pharmacological 
approaches proposed to restore a global intracellular activity of the PQC system. Collectively, these 
data suggest that the fine and delicate equilibrium existing among the different players of the PQC 
system could be restored in a therapeutic perspective by the synergic/additive activities of 
compounds designed to tackle sequential or alternative steps of the intracellular defense 
mechanisms triggered against proteotoxic misfolded species.  
 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
INTRODUCTION 
 
Almost all inherited and sporadic neurodegenerative diseases are characterized by the presence of 
proteins that, either because of their natural structure, and/or as a consequence of genetic 
mutation(s), have a tendency to aberrantly fold (misfold), generating uncommon conformations. 
When this happens, these proteins become prone to oligomerize and/or aggregate. These misfolded 
proteins, either in their monomeric, oligomeric or aggregated form, are recognized by the protein 
quality control (PQC) system,  which surveys proteostasis, by facilitating the removal of potentially 
toxic species and/or attenuating their translation (Carra, et al., 2013,Seguin, et al., 2014). However, 
when not properly disposed, these aberrant misfolded species can exert toxic effects, thereby 
contributing to cell vulnerability and death. In presence of aberrantly folded species, the PQC 
system activates the so called proteotoxic stress response, which involves: a) the chaperone proteins, 
including members of the heat shock protein (HSP) family, and the two major intracellular 
degradative systems, comprising the b) ubiquitin-proteasome system (UPS) and c) the autophagy-
lysosome pathway (ALP). Molecular chaperones recognize the misfolded species and assist their 
refolding; when this fails, as in case of misfolded proteins, chaperones assist their clearance by 
cooperating with the degradative systems. ALP can be subdivided into at least three different 
pathways, the macroautophagy (herein referred to autophagy), microautophagy and chaperone-
mediated autophagy (CMA). In addition, even if more indirectly, the unfolded protein response 
(UPR), which involves the endoplasmic reticulum-associated degradation (ERAD), is part of this 
protective mechanism which aims to reduce proteotoxic stress to neurons. The UPR system works 
commonly in conjunction with molecular chaperones to determine the fate of misfolded proteins, 
leading to either re-folding of the protein or UPS/ALP-mediated degradation. Imbalance in the PQC 
system has been described in a number of neurodegenerative diseases (Carra, et al., 2012,Carra, et 
al., 2013,Ciechanover and Kwon, 2015,Kakkar, et al., 2014,Kampinga and Craig, 
2010,Nikoletopoulou, 2015 #4737,Klionsky, et al., 2012,Senft and Ronai, 2015,Xilouri and 
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Stefanis, 2015). Here, we will focus on the role of the PQC in the pathogenesis of Spinal and Bulbar 
Muscular Atrophy (SBMA). In addition, we will discuss why and how boosting specific molecular 
chaperones and/or enhancing the activity of the degradative systems may have beneficial and 
therapeutic implications for SBMA. 
 
SBMA is a protein misfolding disease 
 
 
SBMA, also known as Kennedy's disease, is an inherited X-linked motor neuron disease (MND) 
mainly characterized by motor neuron loss in the brain stem and in the anterior horns of the spinal 
cord. However, other cell types are also directly affected, such as dorsal root ganglia (DRG) 
sensory neurons and some cells involved in male reproductive functions (Atsuta, et al., 
2006,Fischbeck, 1997,Kennedy, et al., 1968,La Spada, et al., 1991,Malena, et al., 2013,Soraru, et al., 
2008). In recent years, a significant contribution of muscle has emerged in SBMA as in other 
MNDs (Boyer, et al., 2013a,Boyer, et al., 2013b). Indeed, recent data suggests that muscle 
pathology maybe a primary player in the pathogenesis of SBMA, underscoring the importance of 
exploring therapeutic approaches targeting muscle as well as motor neurons (Cortes, et al., 
2014a,Lieberman, et al., 2014,Rinaldi, et al., 2014). Most of the cells that are affected in SBMA are 
postmitotic (Campisi and d'Adda di Fagagna, 2007,Grunseich, et al., 2014b), and their loss give rise 
to a variety of symptoms. The most debilitating of these symptoms are caused by atrophy of bulbar, 
facial and limb muscles (Fratta, et al., 2014b,Kennedy, et al., 1968,Sobue, et al., 1989), alterations in 
sensory function (Adachi, et al., 2005,Atsuta, et al., 2006,Polo, et al., 1996,Suzuki, et al., 2008), as 
well as specific endocrine alterations (Fischbeck, 1997,Fischbeck, 2012). The molecular basis of 
the disease is associated with an expansion of a CAG triplet repeat sequence, that codes for the 
amino acid glutamine (Q), located in exon 1 of the androgen receptor (AR) gene (La Spada, et al., 
1991). In the normal population, this CAG repeat is comprised between 9 and 37 repeats 
(average=22), but in SBMA patients, expansions of more than 38 (up to 68) repeats (Fratta, et al., 
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2014a,Grunseich, et al., 2014a) results in disease. The CAG repeat codes for a polyglutamine 
(polyQ) tract, which is located in the N-terminal transactivation domain of the AR (ARpolyQ) 
protein. The elongated polyQ confers toxicity to the ARpolyQ, but in a ligand dependent manner 
(figure 1) (Katsuno, et al., 2003,Katsuno, et al., 2002). This toxicity has been linked to the 
acquisition of polyQ-induced aberrant protein conformations (misfolding), which are prone to 
aggregation. The excess of misfolded ARpolyQ may perturb the PQC system, specifically in cells 
expressing high levels of ARpolyQ, which include both neuronal and non-neuronal cells including 
lower spinal cord motor neurons, DRG neurons, muscle cells, Sertoli and Leydig cells.  
 ARpolyQ nuclear inclusions were first identified back in 1998 by Li and colleagues in several 
autopsy tissues from SBMA patients (Li, et al., 1998a). These inclusions are heavily ubiquitinated, 
a clear index of alteration of UPS-mediated degradation. They are also particularly reactive with 
antibodies recognizing the N-terminus of the AR, suggesting that they originate from proteolytic 
cleavage of the AR. The nuclear inclusions were found in spinal and brainstem motor neurons, but 
not in unaffected neural tissues, although they were also present in several different non-neural 
tissues (Li, et al., 1998b). Subsequent studies further characterized their intracellular distribution in 
affected neurons, and showed that ARpolyQ inclusions are present in nuclei of spinal cord motor 
neurons and the cytoplasm of DRG sensory neurons (Adachi, et al., 2005,Suzuki, et al., 2008). In 
muscle, inclusions were mainly found in nuclei (Li, et al., 1998b). Subsequently, we and others 
were able to show that in reconstituted motor neuronal systems these inclusions are formed 
exclusively after ARpolyQ activation either by its endogenous ligand testosterone (or the 
testosterone derivative, dihydrotestosterone, DHT) (Simeoni, et al., 2000,Stenoien, et al., 1999), or 
by some (but not all, i.e. bicalutamide or casodex) specific AR selective modulators (SARMs), such 
as cyproterone acetate (Rusmini, et al., 2007,Whitaker, et al., 2004). However, it is still not clear 
why ARpolyQ toxicity strictly depends on androgens. Several data suggest that testosterone triggers 
ARpolyQ toxicity by inducing a switch in its structure from “non-toxic” to “toxic” conformations, 
which generates ARpolyQ aggregates (Simeoni, et al., 2000). Thus, both the process of misfolding 
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and the consequent aggregation possibly occur during the androgen-induced AR maturation to its 
active form (Poletti, 2004,Poletti, et al., 2005). The AR maturation/activation process requires the 
ligand-induced dissociation from HSPs proteins (Figure 1). This step allows the unmasking of the 
polyQ tract of the AR, which may then act either intramolecularly (intrinsic propensity to misfold), 
preventing proper folding because of its elongated size, or intermolecularly (extrinsic propensity to 
oligomerize and possibly aggregate), by its interaction with other polyQs in different ARpolyQ 
molecules. Moreover, ARpolyQ could interact with non-polyQ proteins able to exacerbate 
ARpolyQ misfolding (see (Poletti, 2004) for review) and possibly ARpolyQ cleavage, with the 
consequent release of a potentially "super-toxic" N-terminal fragment containing the polyQ repeat. 
This process has long been considered one of the major steps required for the acquisition of 
ARpolyQ toxicity. However, recent data have raised the possibility that caspase mediated release of 
ARpolyQ fragments may not be the cause of cell death. In fact, while the "toxic fragment" may 
directly induce neuronal dysfunction and death in a soluble form, its toxicity could be buffered by 
its sequestration into amyloid-like inclusions. The fragment containing the polyQ may also 
contribute to (or initiate) the seeding process required to generate aggregates in many misfolded 
protein diseases. However, the ARpolyQ proteolysis is a late event in SBMA mice, and most of the 
ARpolyQ aggregates that originate in the early stage of the disease contain the full-length protein. 
Finally, the ARpolyQ undergoes cleavage to a smaller fragment via the UPS, and only after its 
incorporation into intranuclear inclusions (Heine, et al., 2015), further supporting the possibility 
that ARpolyQ fragments may not be the “culprit”. 
An alternative, but not exclusive mechanism proposed to explain the ligand-induced toxicity to 
ARpolyQ is based on the fact that testosterone induces nuclear translocation of ARpolyQ. Several 
lines of evidence have demonstrated that the nucleus is the site where ARpolyQ exerts most of its 
toxic effects (Montie, et al., 2009,Montie, et al., 2011,Nedelsky, et al., 2010). A specific 
interdomain interaction, which is required for the nuclear activities of AR, is also crucial for 
ARpolyQ aggregation and toxicity. This is the amino-terminal FXXLF motif capable of interacting 
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in a ligand-dependent manner with the carboxyl-terminal AF-2 domain (N/C interaction). Genetic 
mutation of the FXXLF motif can prevent ARpolyQ aggregation and toxicity (Orr, et al., 2010). 
Apart from the molecular mechanisms of aggregation, during this phenomenon, the aggregating 
ARpolyQ also sequesters several other proteins which are fundamental for cell functions. These 
include proteins that can associate to the AR (e.g.: CREB and the steroid receptor coactivator 1; 
SRC-1), or proteins recruited by misfolded species during their processing (e.g. proteins involved in 
the PQC, like NEDD8, HSP70, HSP90 and HDJ-2/HSDJ or also components of the PA700 
proteasome caps, but not 20S core particles) (Stenoien, et al., 1999). 
While the original interpretation suggested that aggregates/inclusions of ARpolyQ were responsible 
for motor neuronal death, other data revealed that this process may be more complex than expected. 
A recent study performed with atomic force microscopy (AFM) has focused attention to inclusions 
normally generated by the wild-type (wt) AR (a protein particularly prone to aggregate even in its 
normal aminoacid sequence) in aged tissue, and compared these inclusions with those produced by 
the ARpolyQ in SBMA (Jochum, et al., 2012). The results evidenced the existence of annular 
oligomers (120-180nm in diameter) for the wtAR and of small oligomeric fibrils (up to 300-600nm 
in length) for the ARpolyQ, similar to those described by us and others in SBMA (Li, et al., 
2007,Palazzolo, et al., 2008) and also similar to inclusions described in other related CAG/PolyQ 
neurodegenerative diseases. Thus, the elongated polyQ seems to exacerbate the natural propensity 
of wtAR to aggregate, but with a distinct aggregate maturation.  
Whether these steps are associated with the intrinsic properties of the ARpolyQ, to a deleterious 
activity of the ARpolyQ on the degradative system, or rather due to its insufficient handling and 
clearance by an overwhelmed PQC system is still matter of discussion. It is conceivable that all of 
these mechanisms are involved, and the accumulation of ARpolyQ depends on a reduced capability 
of aged cells to counteract the intrinsic tendency of ARpolyQ to generate immature inclusions. In 
general, it is accepted that the aggregation process occurs through several successive steps that 
require misfolded protein oligomerization into soluble deposits, with generation of different 
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peculiar structures, followed by maturation into insoluble fibrils. In SBMA mice, ARpolyQ 
oligomers appear several weeks prior to symptom onset and are rather soluble, since they disappear 
after testosterone removal by castration. Thus these aggregates are structurally distinct from 
intranuclear inclusions that appear at later stages (Li, et al., 2007). With these subsequent steps, the 
formation of ARpolyQ aggregates may initially serve to protect cells from the aberrant toxic 
conformation of ARpolyQ. In fact, during aggregation, these toxic species are sequestered into a 
physically defined subcellular compartment (the aggregate), waiting for their possible intracellular 
degradation (see below) (Arrasate, et al., 2004,Klement, et al., 1998,Rusmini, et al., 2007,Saudou, 
et al., 1998,Simeoni, et al., 2000). However, if not removed, at later stages and possibly because of 
reduced PQC activity in aged cells, ARpolyQ aggregates may then have impact on several other 
intracellular mechanisms, thus becoming toxic to cells (Piccioni, et al., 2002,Piccioni, et al., 
2001,Poletti, 2004), by affecting several different intracellular functions. Therefore, the toxic role of 
aggregates is rather controversial, although the search for the "toxic specie(s)" of ARpolyQ (and of 
other polyQ containing proteins) is still in progress. 
 
The protein quality control system in SBMA 
Besides the search for the "toxic specie(s)", the presence of insoluble ARpolyQ in affected SBMA 
cells is the index of defective activity of the PQC system.  
a) The Chaperones 
The first line of defense of the PQC system is represented by several families of HSPs. HSPs act as 
molecular chaperones capable of both recognizing and stabilizing misfolded proteins, including 
ARpolyQ (figure 1). The effect of a variety of chaperones has been tested on ARpolyQ clearance, 
accumulation and aggregation in different models of SBMA. The heat shock factor-1 (HSF-1), 
which is a transcriptional regulator of HSPs, strongly reduces ARpolyQ aggregation by enhancing 
the levels of different HSPs; thus, with a rather aspecific mechanism associated with the pan-
activation of the heat shock response (Kondo, et al., 2013). The mediators of the anti-aggregation 
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chaperone activity have been identified mainly in the combined activities of HSP70 and HSP40 
(Figure 1), and of HDJ2/HSDJ (Adachi, et al., 2003,Bailey, et al., 2002,Howarth, et al., 
2007,Kobayashi, et al., 2000,Stenoien, et al., 1999). Other chaperones active against ARpolyQ 
aggregation include HSP90, HSP105 (Adachi, et al., 2009,Ishihara, et al., 2003,Katsuno, et al., 
2005) and the DnaJ-like-1 (HSJ1) proteins (which contain DnaJ and ubiquitin-interacting motifs) 
(Howarth, et al., 2007). As mentioned above, these chaperones are often sequestered into ARpolyQ 
inclusions, and/or their levels in affected cells may be significantly reduced. In general, their 
overexpression correlates with a reduction in the total amount of insoluble ARpolyQ accumulated 
in neuronal cells (Adachi, et al., 2009). The complex interplay between the chaperones and the 
ARpolyQ has been extensively reviewed in (Pratt, et al., 2014), in which the Authors proposed that 
the misfolded ARpolyQ accumulates as a consequence of being a "client" of HSP90, which is then 
recognizable by the other HSPs. The same concept is applied to other misfolded polyQ containing 
proteins (e.g. huntingtin, (HD)) or mutant proteins associated with other neurodegenerative diseases 
(e.g.: tau (AD), α-synuclein (PD)). In these models, HSP90 exerts its action by acting on a specific 
protein-folding cleft, which can be used to drive the clearance of the client protein (Pratt, et al., 
2014). In addition, the overall power of molecular chaperones against ARpolyQ aggregation may 
depend both on the type of chaperones, and on their specific combinations (e.g.: synergic activity of 
HSP70 with its co-chaperone HSP40) (Kobayashi, et al., 2000,Stenoien, et al., 1999). For example, 
HSP70, HSP40, HSJ1a and HSJ1b have all been shown to reduce ARpolyQ inclusions, HSP70 and 
HSP40 increase chaperone-mediated refolding, while HSJ1 proteins mainly avoid ARpolyQ 
aggregation and assist its ubiquitination and UPS-mediated degradation, without promoting its 
refolding (Howarth, et al., 2007). Another HSP70 interactor, the C-terminus of HSC70 (heat shock 
cognate protein 70)-interacting protein (CHIP), which has a U-box type E3 ubiquitin ligase activity, 
has been shown to be a potent modulator of ARpolyQ accumulation. Following interaction with 
HSP70, CHIP can ubiquitinate the ARpolyQ entrapped by the chaperone machinery, allowing its 
subsequent degradation by the PQC degradative pathway (Figure 1) (Adachi, et al., 2007). Indeed, 
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in studies performed on neuronal models of SBMA, CHIP greatly reduced ARpolyQ accumulation, 
while CHIP overexpression in a SBMA transgenic mouse model resulted in a clear amelioration of 
the motor behavior of affected mice, accompanied with a reduced neuronal nuclear accumulation of 
ARpolyQ (Adachi, et al., 2007). 
It is not only the classical ATP-dependent HSPs that can exert anti-aggregation activity on 
ARpolyQ, but also small ATP-independent HSPs, such as HSPB8 (Carra, et al., 2005,Rusmini, et 
al., 2013) which are potent inhibitors of ARpolyQ aggregation. In vitro, HSPB8 displays chaperone 
activity (Carra, 2009,Carra, et al., 2012,Carra, et al., 2013,Carra, et al., 2008a,Carra, et al., 
2008b,Rusmini, et al., 2013). In cells, HSPB8 forms a complex with BAG3, a co-chaperone of 
HSP70, and promotes the degradation of misfolded proteins resistant to HSPs-dependent refolding 
(Figure 1). Degradation of the bound substrate (ARpolyQ and several other disease-associated 
misfolded proteins) occurs via autophagy rather than via the UPS and in different cell types, 
including motor neurons, HeLa cells, COS cells and HEK293T cells (Carra, et al., 2012,Crippa, et 
al., 2010b,Gamerdinger, et al., 2011,Rusmini, et al., 2013). 
 
b) The Proteasome 
When the first PQC defense line is activated, but refolding fails, specific chaperones assure cell 
protection against proteotoxicity by routing misfolded proteins to the degradative systems (UPS and 
autophagy) (Figure 1). With regards to proteasome, misfolded proteins are recognized by several 
different chaperones (mainly the HSP70/HSP40 complex), which allows the selective ubiquitination 
of the target misfolded substrates (mediated by the complex system of the ubiquitin ligases) to be 
directed to the 20S core of the proteasome for degradation (Figure 1). Both the wtAR and the 
ARpolyQ are efficiently processed by the proteasome, and inhibition of the UPS results in 
accumulation of large amounts of AR (either wt or mutant) in neuronal and non-neuronal cells 
(Dossena, et al., 2014,Rusmini, et al., 2010,Rusmini, et al., 2013,Rusmini, et al., 2007,Rusmini, et 
al., 2011). It is unclear whether neuronal cells have a different UPS vs autophagic power compared 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
to other cell types (Crippa, et al., 2013b,Galbiati, et al., 2014,Onesto, et al., 2011), but possible 
modifications to the equilibium between these two pathways may be responsible for selective 
modification of ARpolyQ clearance in different cells.  
It has been shown that the propensity of ARpolyQ to form insoluble species is accentuated in 
neuronal cells, possibly because of a less efficient PQC system compared to other cell types. In fact, 
using SBMA patient derived iPSCs cells, Nihei and colleagues showed that ligand-induced 
ARpolyQ aggregation can be detected in filter retardation assays (FRA) only in cells differentiated 
to a motor neuronal phenotype, and not in undifferentiated iPSCs or fibroblasts from SBMA 
patients (Nihei, et al., 2013). However, in non-neuronal cells, such as adipose mesenchymal cells 
derived from SBMA patients, inhibition of the PQC (in this particular case, the inhibition of 
proteasome, but not of autophagy) induces ARpolyQ accumulation into ubiquitinated and HSP70 
positive nuclear aggregates (Dossena, et al., 2014). Because of its structure, the wtAR is already 
prone to aggregate (Jochum, et al., 2012), and the AR utilizes the same route of degradation, which 
is normally based on the proteasome. However, the presence of the elongated polyQ makes this 
protein more resistant to UPS handling and degradation, and the long polyQ may impair and/or 
overwhelm the proteasome capabilities; as a consequence this phenomenon will require the 
involvement of the autophagic pathway, which is an alternative pathway of degradation 
characterized by lower selectivity, but higher capacity than the UPS (see (Rusmini, et al., 2010) for 
review). The aggregates therefore serve to temporarily sequester those fractions of ARpolyQ 
misfolded species that may have direct impact on the UPS. Indeed, by analyzing UPS functions 
during ligand-induced ARpolyQ cytoplasmic aggregation, we clearly noted that the proteasome 
reporter, YFPu, accumulates in absence of ARpolyQ aggregates (untreated ARpolyQ is cleared by 
the UPS, thus impairing the pathway), but testosterone-induced ARpolyQ aggregation correlates 
with a normal YFPu clearance (Rusmini, et al., 2007). Thus, aggregation contributes to proteasome 
desaturation (but this effect is not related to AR nuclear translocation), protecting the proteasome 
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from an excess of misfolded protein to be processed, and the forming aggregates then have to be 
processed by the autophagic pathway.  
c) Autophagy 
Autophagy may take place in different cytoplasmic regions and the insoluble forms of ubiquitinated 
ARpolyQ are recognized by specific proteins, including p62/SQSTM1. p62/SQSTM1 interacts with 
the autophagosome associated lipidated form of LC3 (LC3-II) and is engulfed into nascent 
autophagosomes; later, these autophagosomes fuse to lysosomes, where misfolded proteins and 
aggregates are degraded (Figure 1). Misfolded species can also be directed to the microtubule 
organization center (MTOC) in a microtubule and dynein dependent manner (Figure 1) (Johnston, 
et al., 2002,Webb, et al., 2004). Here, misfolded species can form the so called "aggresomes" to 
facilitate engulfment into the nascent autophagosomes (Fujinaga, et al., 2009,Iwata, et al., 
2005,Johnston, et al., 2002,Johnston, et al., 1998,Kopito, 2000,Kopito and Ron, 2000,Taylor, et al., 
2003). The MTOC region is particularly enriched of autophagosomal components (Johnston, et al., 
2002). Depletion of the essential autophagic component p62/SQSTM1 results in an earlier disease 
onset and a worsening of motor deficits in a transgenic SBMA mice model (Doi, et al., 2013), 
which correlate with increased levels of insoluble ARpolyQ in affected cells. In addition, in an 
autophagy related manner, p62/SQSTM1 silencing increased, while p62/SQSTM1 overexpression 
reduced, the total amounts of monomeric soluble and oligo/heteromeric insoluble complexes of 
ARpolyQ in cultured cells and in transgenic SBMA mice (Doi, et al., 2013). If the proteasome is 
responsible for wt and ARpolyQ degradation in basal conditions, and autophagy takes over only 
when the UPS is impaired or overwhelmed, the accumulation of ARpolyQ (in particular in nuclear 
inclusion) may be linked to a defect in the secondary activation of the protective cytoplasmic 
autophagic pathway, rather than to an initial failure in proteasome function. A delicate equilibrium 
exists between the UPS and autophagy, which are both essential for the correct functioning of the 
PQC system (Carra, et al., 2012,Carra, et al., 2013,Rusmini, et al., 2010,Rusmini, et al., 2013). The 
ARpolyQ re-routing from the proteasome to autophagy may be of relevance for its clearance and it 
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requires specific chaperones that are able to sense proteasome inhibition, such as HSPB8 (Crippa, et 
al., 2010a,Crippa, et al., 2010b) and the co-chaperones BAG3 (for autophagic clearance) and BAG1 
(for UPS clearance) (Figure 1) (Gamerdinger, et al., 2011). The complex HSPB8 and BAG3 (in a 
2:1 ratio) interacts both with misfolded proteins and with HSC70/CHIP for substrate ubiquitination 
(Figure 1) (Arndt, et al., 2010,Crippa, et al., 2010a,Crippa, et al., 2010b). It is of note that 
conditions that lead to proteasome overwhelming and/or impairment result in a selective "de novo" 
transcriptional activation of the HSPB8 promoter (Crippa, et al., 2010b). The raised levels of 
HSPB8 permit an increase in the total amount of the 2x(HSPB8)/BAG3 complex, with an 
enhancement of its overall activity against misfolded species (Crippa, et al., 2010a). Interestingly, 
we found that HSPB8, by interacting with BAG3, decreases ARpolyQ aggregation, by increasing 
its solubility and clearance (Rusmini, et al., 2013). In motor neuronal cells, HSPB8 does not modify 
the expression of p62 and LC3 (the two key autophagic molecules). However, HSPB8 prevents p62 
body formation, restoring a normal autophagic flux, which is known to be impaired by testosterone-
activated ARpolyQ (Rusmini, et al., 2013). As a consequence of the restored autophagic flux, 
HSPB8 facilitates the ARpolyQ autophagic removal, thereby limiting its aggregation and toxicity in 
motor neuronal cells (Carra, et al., 2013,Crippa, et al., 2010a,Crippa, et al., 2010b,Rusmini, et al., 
2013). Upregulation of the HSPB8-BAG3 complex may thus play a key role in the defense against 
ARpolyQ and in the maintenance of motor neuron viability. Notably, HSPB8 is mutated (at K141 
with E or N) in some forms of motor neuron diseases (Charcot-Marie-Tooth type 2L disease and in 
hereditary distal motor neuropathy type II (dHMNII) (Fontaine, et al., 2006,Irobi, et al., 2010)), and 
the chaperone activity of HSPB8 is lost in the mutant dHMNII-HSPB8 (Kwok, et al., 2011). This 
supports the possibility that HSPB8 is crucial for motor neuron function and viability. Moreover, in 
ALS mice, both anterior horn spinal cord motor neurons and skeletal muscle cells respond to 
proteotoxicity by activating a robust HSPB8-mediated PQC system response (Crippa, et al., 
2013a,Crippa, et al., 2013b,Crippa, et al., 2010b). Furthermore, the motor neurons that survive in 
the spinal cord at disease end stage have particularly enhanced levels of HSPB8 protein in 
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association with soluble mutant SOD1 (Crippa, et al., 2010b). Similar data have been reported in 
autopsy specimens of ALS patients spinal cord (Anagnostou, et al., 2010). It must be noted that in 
mouse spinal cord, HSPB8 expression level decline with age (Crippa, et al., 2010b), suggesting that 
motor neuronal cells may become more vulnerable to misfolded protein toxicity during aging, as a 
result of low levels of this pro-autophagic protein. HSPB8 also exerts a physiological role in the 
PQC response in muscle (Arndt, et al., 2010), another target of ARpolyQ toxicity. However, 
although the expression levels of HSPB8 dramatically increase with disease progression in muscle 
of ALS mice (Carra, et al., 2013,Crippa, et al., 2013a,Crippa, et al., 2013b), nothing is known at 
present about the possible involvement of the HSPB8 and BAG3 machinery in SBMA skeletal 
muscle. Our preliminary results suggest that in symptomatic SBMA male mice, the expression level 
of HSPB8 in muscle is increased, but not at levels comparable to those found in the corresponding 
muscles of symptomatic ALS mice. 
As stated above, many of the genes involved in autophagy have been found altered in response to 
ARpolyQ expression or activation by ligands. However, one of the most relevant defects is 
associated with the fact that ARpolyQ is able to reduce the long-term proteins turnover and to block 
the cytoplasmic autophagic flux (Carra, et al., 2012,Cortes, et al., 2014b,Giorgetti, et al., 
2014,Rusmini, et al., 2010,Rusmini, et al., 2013,Rusmini, et al., 2007,Rusmini, et al., 2011). As will 
be discussed in the next sections, the pharmacological restoration of a normal autophagic flux, for 
example by treatment with trehalose, a TFEB activator (Dehay, et al., 2010), greatly increases the 
clearance of the mutant misfolded ARpolyQ (Giorgetti, et al., 2014,Rusmini, et al., 2013). Defects 
in autophagy flux have been clearly identified in SBMA mice (Cortes, et al., 2014b), and the 
importance of autophagy in SBMA is confirmed by several recent studies (Cortes, et al., 
2014b,Settembre and Ballabio, 2011). The ARpolyQ processing may differ considerably in 
neuronal and muscle cells, both targets of ARpolyQ toxicity, and the identification of specific 
autophagy related molecular markers of skeletal muscle degeneration in SBMA might represent a 
valuable diagnostic tool for monitoring disease progression. In SBMA muscle, the toxicity of 
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activated ARpolyQ is rather complex and controversial, and autophagy may exert either a 
protective or a detrimental effect. Autophagy is dysregulated in muscle of AR113Q knock-in 
SBMA mice, and autophagic genes appear to be regulated by a physiological antagonism between 
TFEB and ZKSCAN3 (Chua, et al., 2014), which surprisingly, are both greatly increased. In muscle 
of SBMA mice, TFEB levels are increased, and consequently most of the TFEB-target genes are 
upregulated, including LC3, Vps11, Vps18 and Lamp1 (Chua, et al., 2014). Inhibition of Beclin-1 
induced autophagy diminished skeletal muscle atrophy in AR113Q knock-in SBMA mice, 
improved motor behavior and extended lifespan (Yu, et al., 2011). On the other hand, over-
activation of autophagy worsened the motor phenotype (Yu, et al., 2011). Therefore, restoration of 
both a normal flux and a dysregulated autophagy may help in the ARpolyQ clearance in muscle of 
SBMA mice.  
 
d) Endoplasmic Reticulum-Associated Degradation in stress conditions and the Unfolded Protein 
Response. 
Alteration of the proteasomal and/or autophagic pathways may involve a proteotoxic response to 
cell stress that induces the unfolded protein response (UPR) at the level of the endoplasmic 
reticulum (ER). The UPR is normally activated in the ER lumen to restore normal cell function via 
transient translational blockage, activation of degradative pathways and induction of molecular 
chaperones. When protein misfolding occurs, hydrophobic aminoacids are usually exposed to the 
surface of the protein, which can be recognized by proteins such as BiP/Grp78, a member of the 
HSP70 family. These proteins can be driven to the ER-associated degradation (ERAD) to initiate 
the signaling of the UPR, involving factors including PKR-like endoplasmic reticulum kinase 
(PERK) and inositol requiring enzyme 1 (IRE1) (Figure 1). Translation attenuation is mediated by 
the PERK receptor soon after UPR initiation, and induced by PERK oligomerization and 
autophosphorylation, and involves phosphorylation of the eIF2 mRNA translation machinery. At 
the same time, the mRNA coding for the transcription factor XBP1 is activated by alternative 
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splicing and the resulting protein product upregulates the transcription of UPR stress genes. In 
addition, the activating transcription factor 6 (ATF6) is activated by protein cleavage, migrates from 
the ER to the nucleus, where it controls other UPR genes. These simultaneous activities lead to the 
restoration of normal ER functions. It has been shown, using a disease-associated fragment of the 
ARpolyQ, that this is capable of activating an ER stress-inducible promoter. When the contribution 
of the three proximal sensors of ER stress, ATF6, IRE1, and PERK, to the UPR was analysed in 
detail, it was found that ARpolyQ toxicity increased when ATF6 was blocked, but decreased by 
overexpression of a constitutively active mutant of ATF6. Conversely, modification of the IRE1 
arm of UPR did not modify ARpolyQ toxicity, whilst PERK activation resulted in increased 
ARpolyQ toxicity (Thomas, et al., 2005). Thus, the UPR is activated by ARpolyQ and UPR 
activation may reduce its toxicity. ARpolyQ induced toxicity in skeletal muscle also induces the 
UPR. In knock-in SBMA mice, characterized by muscle atrophy induced by Beclin-1 mediated 
autophagy, deletion of the transcription factor C/EBP homologous protein (CHOP), which is 
normally induced following ER stress, significantly increased muscle atrophy, proving the existence 
of a cross-talk between the UPR and macroautophagy in SBMA (Yu, et al., 2011).  
In mouse embryonic stem cells (ESCs), ARpolyQ is able to induce a testosterone-dependent cell 
stress phenotype during cell differentiation, characterized by the formation of ARpolyQ inclusions 
positive for E3 ubiquitin ligase, CHIP and BiP/GRP78, as well as by Caspase-3 activation. 
ARpolyQ aggregation was accompanied by ER stress and increased susceptibility to apoptosis. 
These modifications were paralleled by a robust increase in levels of ER chaperones (GRP78/BiP 
and GRP94) and ER stress markers (ATF6, phosphorylated PERK, GADD153/CHOP and spliced 
XBP-1). ARpolyQ activation was also responsible for the dissociation of BiP/GRP78 from ATF6. 
Interestingly, exogenous overexpression of GRP78/BiP reduced ARpolyQ ubiquitination and 
aggregation, while GRP78/BiP silencing of GRP78/BiP correlated with increased ARpolyQ 
aggregation, caspase-3 activity and cell apoptosis (Yang, et al., 2013). 
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The ER may be regarded as a quality control system for newly synthesised proteins in cells. The ER 
is associated not only with protein folding, but also the control of Ca2+ homeostasis and is the main 
intracellular Ca2+ reservoir (Hetz and Mollereau, 2014). Therefore, accumulation of misfolded 
proteins within the ER and/or depletion of ER Ca2+ may compromise normal cellular function and 
subsequently trigger ER stress. The mechanisms that attempt to restore ER homeostasis include 
store-operated Ca2+ influx, which replenishes Ca2+ levels, as well as activation of the UPR 
(Szegezdi, et al., 2006). Sustained activation of ER stress diminishes the ability of the UPR to 
restore ER homeostasis and results in ER stress-induced apoptosis, mediated by caspase 12 
(Yoneda, et al., 2001). The role of ER stress and Ca2+ homeostasis was recently examined in the 
AR100 mouse model of SBMA. AR100 mice develop a late onset, slowly progressive 
neuromuscular phenotype, accompanied by motor neuron degeneration and muscle atrophy (Malik, 
et al., 2011,Montague, et al., 2014,Sopher, et al., 2004). Dysregulation of Ca2+ homeostasis in 
embryonic motor neurons of AR100 mice results in ER stress, which enhances the vulnerability of 
AR100 motor neurons to ER-stress-induced apoptosis (Montague, et al., 2014). These findings 
suggest that in cultured motor neurons of AR100 SBMA mice, ligand-dependant DHT activation of 
ARpolyQ triggers a depletion of ER Ca2+ levels and a reduction of store-operated Ca2+ influx. As a 
consequence, ER stress is more likely to occur in AR100 embryonic motor neurons, as the normal 
function of the ER is dependent on Ca2+ levels (Hetz and Mollereau, 2014,Tadic, et al., 2014). The 
reduction in ER Ca2+ may in part be explained by the finding that the expression of the SERCA2b 
pump was significantly lower in AR100 motor neurons than in wildtype motor neurons. SERCA2b 
belongs to the sarcoendoplasmic reticulum Ca2+ ATPases (SERCAs) which enable ER Ca2+ re-
uptake (Foradori and Handa, 2008). Furthermore, the levels of the ER stress markers BiP, ATF4 
and CHOP were all also significantly elevated in DHT-treated AR100 embryonic motor neurons in 
vitro. As a result, ER stress-mediated apoptosis was activated in AR100 motor neurons in vitro, 
leading to an increase in the expression of activated caspase 12. Similarly, there was elevation of 
ER stress markers in vivo, in spinal cord motor neurons of AR100 mice (Montague, et al., 2014). 
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Importantly, this ER stress was detected in presymptomatic mice, long before the onset of any 
pathology and development of disease, suggesting that ER stress may be an early event in the 
pathogenesis of SBMA which possibly plays a causal role in the development of the disease.  
Furthermore, preliminary findings suggests that there is a difference in activation of the ER stress in 
muscle compared to spinal cord in AR100 mice, indicating that there may be an alternative 
mechanism responsible for muscle dysfunction in SBMA (Malik and Greensmith, unpublished 
observation). 
 
Approaches aimed to enhance the activity of the protein quality control system to counteract 
ARpolyQ toxicity in SBMA 
The findings discussed so far indicate that the PQC system exerts protective effects against 
ARpolyQ toxicity. On the other hand, ARpolyQ may impair the PQC system, generating a vicious 
circle in which the reduced activity of the PQC leads to less protection against cell stress induced by 
the ARpolyQ, thereby enhancing its toxicity. As a result, several investigators have developed 
different approaches aimed to improve the overall activity of the PQC system in neurons or muscle 
cells. Indeed, the simple overexpression of chaperones and/or the stimulation of autophagic 
pathway have been shown to positively modulate ARpolyQ deposition, and to reduce its toxicity.   
 
a) Enhancement of the chaperone response 
One of the first attempt to increase the chaperone response in models of SBMA involved the use of 
Geranylgeranylacetone (GGA), a nontoxic anti-ulcer drug, which has been shown to stimulate 
Hsp70, Hsp90 and Hsp105 expression (Katsuno, et al., 2005). In transgenic SBMA mice, oral GGA 
treatment induced a significant enhancement of the chaperone activity mediated by these HSPs, 
resulting in an amelioration of neuromuscular deficits and an increase in survival. This protective 
effect of GGA was mediated by a significant reduction in ARpolyQ accumulation in the affected 
areas of the central nervous system (Adachi, et al., 2009,Katsuno, et al., 2005). Unfortunately, 
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although oral GGA was well tolerated in mice, the effective dose was very high, so that translation 
to humans patients would be likely to cause significant side effects. Further studies by other groups 
have shown that specific lysine (Lys) residues of the wtAR (acetylated in a ligand-dependent 
manner) may significantly affect AR dynamics, inducing a behavior (in term of trafficking, 
misfolding, and aggregation) similar to that caused by ARpolyQ. When the Lys 630 or 632 and 633 
are converted to alanine (K/A conversion), wtAR nuclear translocation is greatly delayed, 
accompanied by the formation of inclusions that entrap HSP40, HSP70 and the ubiquitin-protein 
isopeptide ligase (E3) CHIP. This aberrant activity can be blocked with radicicol, an inhibitor of 
Hsp90, suggesting that the ligand-dependent K/A ARpolyQ intracellular distribution, folding and 
aggregation are linked to Hsp90 functions (Thomas, et al., 2004). Whether or not the effect of 
radicicol is extended to ARpolyQ, and whether this approach may have relevance for SBMA 
remains to be tested. 
Following these two initial proofs of principle, other molecules targeting the chaperone response 
have been tested in SBMA models. For example, geldanamycin and other related HSP90 inhibitors 
can activate heat shock factor 1 (HSF-1), which in turn results in an enhanced expression of HSP70 
and HSP40. Surprisingly, treatment with geldanamycin completely prevented ARpolyQ aggregate 
formation in HSF-1(-/-) mouse embryonic fibroblasts, in which HSP70 and HSP40 cannot be 
induced by HSF-1 (Thomas, et al., 2006). Since geldanamycin also inhibits HSP90-mediated 
trafficking in cells it may also act via HSP90-dependent trafficking that involves the immunophilins 
(IMM). As a proof of concept, overexpression of p23, a co-chaperone of HSP90, was able to inhibit 
both ARpolyQ trafficking and aggregation (Thomas, et al., 2006). Thus, different druggable sites 
can be identified in the chaperone system that plays a role in the response to proteotoxicity. 
A study using Drosophila models of SBMA has demonstrated that some small molecules may act 
by mimicking the activity of HSP70 interacting protein (Hip) (Wang, et al., 2013). Hip is a co-
chaperone that can enhance the binding of HSP70 to the target misfolded substrates. Together with 
HSP70, Hip promotes the ubiquitination of the client ARpolyQ, facilitating its degradation. In this 
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study, a series of small molecules were designed based on the rhodocyanine MKT-077, a known 
interactor of HSP70, and capable of binding the nucleotide-binding domain of ADP, but not ATP-
bound HSP70. A derivative of MKT-077, named YM-1, was able to promote HSP70-dependent 
steps in nNOS maturation, thus possibly favoring the tight-binding form of HSP70 (Wang, et al., 
2013). YM-1 potently stimulated the binding of HSP70 to unfolded substrates, and converted 
HSP70 to its tight-affinity conformation. Hip blocks binding of YM-1 to HSP70, indicating that this 
synthetic co-chaperone uses a mechanism similar to Hip to interact with HSP70. Using this 
mechanism, YM-1 was able to increase ubiquitination and degradation of client ARpolyQ (Wang, 
et al., 2013). YM-1 reduced the accumulation of RIPA-insoluble ARpolyQ species and the number 
of intranuclear inclusions induced by testosterone, but had no effect on soluble ARpolyQ, 
suggesting that YM-1 acts primarily on unfolded AR species. Treatment with YM-1 was also able 
to rescue toxicityin Drosophila expressing ARpolyQ. In fact the DHT-dependent pupal toxicity of 
the ARpolyQ was significantly rescued by YM-1 (Wang, et al., 2013). Thus, the Hip mimetics act 
allosterically, promoting the binding of HSP70 to unfolded substrates, like ARpolyQ, and enhance 
its ubiquitination and degradation (Wang, et al., 2013).  
An alternative approach to modulate chaperone function is based on the use of 17-allylamino-17-
demethoxygeldanamycin (17-AAG), which is a potent HSP90 inhibitor, and an anti-cancer agent 
which is currently in Phase II clinical trials for a variety of cancers. HSP90 is a fundamental protein 
involved in the assembly of the multichaperone complex responsible for the folding, activation and 
assembly of the AR. HSP90 also has an important role in the response to misfolded proteins like 
ARpolyQ (Poletti, 2004). The ARpolyQ has a higher affinity for the HSP90-p23 complex than for 
wtAR (Waza, et al., 2005). Treatment of transgenic SBMA mice with 17-AAG markedly 
ameliorates ARpolyQ-induced motor impairments (Waza, et al., 2005,Waza, et al., 2006b). This 
effect was attributed to the ability of 17-AAG to reduce both the monomeric and aggregated forms 
of ARpolyQ, an effect which is highly selective for ARpolyQ compared to wtAR (Waza, et al., 
2005). The effect of 17-AAG does not simply involved HSP90, but is associated with a mild 
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increase in HSP70 and HSP40 (Waza, et al., 2006a). Interestingly, 17-AAG acts on ARpolyQ by 
enhancing the overall pro-degradative activity in motor neuronal cells, but without impacting on 
proteasome function. 17-AAG clears the misfolded fraction of ARpolyQ and the resulting ARpolyQ 
aggregates by activating the autophagic system (Rusmini, et al., 2011). The effect of 17-AAG on 
the aggregation and clearance of ARpolyQ has been confirmed in iPSCs derived from SBMA 
patients and induced to differentiate to motor neurons (Nihei, et al., 2013). Unfortunately, 17-AAG 
is not well tolerated in humans and cannot be administered orally. A series of compounds have 
therefore been developed to reduce these adverse effects. One of these is 17-
(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), an oral HSP90 inhibitor, 
that can ameliorate motor deficits in SBMA mice, by reducing the levels of monomeric and 
nuclear-accumulated ARpolyQ, and which is far less toxic than 17-AAG (Tokui, et al., 2009). 
Similarly to 17-AAG, 17-DMAG also increases HSP70 and HSP40 expression, thus contributing to 
the enhancement of the chaperone response in motor neuronal cells.  
Recently, Arimoclomol, a novel, well tolerated and orally administrable co-inducer of the heat 
shock response (HSR) and chaperone system, was tested in SBMA mice (Malik, et al., 2013). 
Arimoclomol is a hydroxylamine derivative of Bimoclomol, and has been shown to upregulate the 
expression of HSPs via co-activation of HSF-1 (Hargitai, et al., 2003). Unlike other drugs which 
target chaperone expression and the HSR, Arimoclomol acts as a ‘smart-drug’ and enhances the 
HSR only in cells already under stress in which HSF-1 is already activated, thereby co-inducing the 
HSR rather than actually activating this stress response (Kalmar, et al., 2008,Vigh, et al., 1997). 
This precise targeting of only cells exhibiting a stress response reduces the possibility of non-
specific effects in otherwise unstressed cells, which occurs following the use of other compounds 
that upregulate HSP expression by direct global activation of the HSR which may reflect a more 
generalised stress response that actually results in cell toxicity and death (Kalmar, et al., 2008). In 
the AR100 mouse model of SBMA, treatment with Arimoclomol increased HSP expression only in 
affected tissue (spinal cord and muscle) and not in unaffected regions (e.g. cortex and liver). 
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Moreover, oral administration of AR100 mice with Arimoclomol significantly delayed disease 
progression by preventing motor neuron degeneration, consequently improving the survival of 
functional motor units, reducing muscle atrophy and alleviating the significant deterioration in body 
weight. Importantly, Arimoclomol also improved hindlimb muscle force and contractile 
characteristics. Since Arimoclomol upregulates HSP expression in muscles and the spinal cord of 
AR100 mice, it is likely that its beneficial effects in AR100 mice are a result of its effects both in 
the periphery in muscles under stress, as well as within the CNS in motor neurons. In addition, 
Arimoclomol also upregulated the expression of vascular endothelial growth factor (VEGF), both in 
the spinal cord and hindlimb muscles of diseased AR100 mice. VEGF is known to have 
neurotrophic effects in the survival of motor neurons (Azzouz, et al., 2004,Cvetanovic, et al., 
2011,Jin, et al., 2002,Lambrechts, et al., 2003,Sopher, et al., 2004,Storkebaum, et al., 2005), as well 
as protect against muscle degeneration in neuromuscular diseases (Lambrechts, et al., 
2003,Storkebaum, et al., 2005). VEGF is regulated by the HIF1A transcription factor and as HIF1A 
has been shown to interact with HSPs (Huang, et al., 2009,Isaacs, et al., 2002), this may provide an 
explanation for the upregulation induced by Arimoclomol. Arimoclomol has been previously shown 
to be effective in delaying disease progression in the SOD1G93A mouse model of ALS (Kalmar, et 
al., 2008,Kieran, et al., 2004), and to protect against retinal degeneration in rhodopsin retinitis 
pigmentosa (Parfitt, et al., 2014). It is therefore an attractive therapeutic candidate for SBMA, as it 
has already been shown to be safe and well tolerated in healthy volunteers and patients with ALS 
(Cudkowicz, et al., 2008), and is currently undergoing a phase II/III trial in the USA in SOD1-ALS 
(www.ClinicalTrials.gov), as well as in patients with the inflammatory myopathy inclusion body 
myositis (IBM) (Machado, et al., 2013). 
b) Activation of autophagy  
Several attempts have been made to enhance the overall cellular autophagy power to promote the 
clearance of toxic ARpolyQ species from SBMA affected cells. The advantage of this strategy is 
that autophagy is thought to be selectively regulated in cells which are specifically sensitive to its 
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activation (i.e. hepatocytes, muscle cells and neurons) and therefore it may be possible to identify 
small molecules capable of selectively intervening in neuronal autophagy. The biological relevance 
of autophagy in these cells is related to their energy requirements as well as to the need for 
protection against different proteotoxic or organelle mediated stresses. Thus, the goal for SBMA is 
to identify compounds that increase autophagic clearance of misfolded ARpolyQ selectively in 
SBMA affected cells, motor neurons and/or muscle cells. Using primary cultures of motor neurons 
derived from SBMA mice, Montie and Merry have shown that both the autophagy activator mTOR-
dependent phenoxazine (or AKTi, a potent Akt inhibitor or rapamicyn), and the mTOR-independent 
trehalose, were able to rescue motor neurons from ARpolyQ mediated ligand-dependent death 
(Montie, et al., 2009,Montie and Merry, 2009). In motor neurons, both AKTi (Montie, et al., 2009) 
and trehalose (Giorgetti, et al., 2014,Montie, et al., 2009,Rusmini, et al., 2013) induced the classical 
cytoplasmic punctate distribution of the lipidated form of LC3 (LC3-II) which associated with 
nascent autophagosomes, a clear index of autophagy activation and this correlated with the full 
removal of aggregated, insoluble ARpolyQ (Giorgetti, et al., 2014,Montie, et al., 2009,Montie and 
Merry, 2009,Rusmini, et al., 2013). Other small molecules structurally related to trehalose may 
have the potential to revert ARpolyQ accumulation and aggregation. Trehalose is considered a 
natural osmolyte and/or "chemical chaperone" (Kumar, 2012). Its advantage as a small molecule, 
which is shared by other osmolytes, is that it can cross the blood-brain barrier with high efficiency. 
In addition, its activity can be enhanced by the synergic effects of other compounds that target 
ARpolyQ. Indeed, since, testosterone activates ARpolyQ toxicity by inducing its nuclear 
translocation, the prevention of ARpolyQ localization in the nucleus, combined with an increased 
cytoplasmic clearance may be protective. Notably, cytoplasmic retention of ARpolyQ obtained 
using the selective AR modulator (SARM) Casodex, not only prevented ARpolyQ aggregation and 
toxicity, enhancing motor neuronal survival (Orr, et al., 2010,Rusmini, et al., 2007), but also 
potentiated the pro-autophagic activity of trehalose (Giorgetti, et al., 2014). This synergistic effect 
may be due to an increased time window for the recognition of misfolded ARpolyQ species in the 
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cytoplasm, soon after AR dissociation from HSPs, and their autophagic engulfment prior to 
migration into the nucleus. This, together with improved ARpolyQ autophagic clearance in the 
cytoplasm, leads to an indirect reduction of ARpolyQ nuclear accumulation, preventing its nuclear 
toxicity by maintaining normal motor neuron proteostasis and viability. 
 
Although the toxic effects of ARpolyQ are thought to be exerted at the nuclear level, cytoplasmic 
autophagic degradation of ARpolyQ greatly reduces its toxic effects. Interestingly, the autophagic 
activation that protects SBMA motor neurons has only mild effects on nuclear ARpolyQ 
aggregation, but significant effects on cytoplasmic ARpolyQ aggregation. This pharmacological 
data has been corroborated by evidence obtained in SBMA mice genetically manipulated to produce 
an AR lacking the nuclear localization signal (NLS) (Montie, et al., 2009). In these ARpolyQNLS 
mice, the AR is poorly translocated into nuclei upon androgenic activation, and this correlates with 
a substantial improvement in motor function compared with classical SBMA mice (Montie, et al., 
2009). Furthermore, using a Drosophila model of SBMA, it has also been shown that the retention 
of an ARpolyQ fragment in the cytoplasm ameliorates the disease (Takeyama, et al., 2002). 
Moreover, in cultured motor neurons of ARpolyQNLS mice, the autophagic pathway was capable 
of fully degrading the cytoplasmically-retained ARpolyQ, activated by androgens, suggesting that 
authopagy may even protect against nuclear ARpolyQ toxicity. As mentioned above, trehalose is 
not only a potent autophagic inducer, but also enhances the expression of HSPB8 (Rusmini, et al., 
2013), known to actively participate in the protection against cell stress by assisting the autophagic 
removal of misfolded ARpolyQ. HSPB8 is able to restore a normal autophagic flux. We recently 
screened for a large library of FDA approved drugs for their ability to stimulate the HSPB8 
promoter in a reconstituted transcriptional assay. Several estrogenic compounds (and selective 
estrogen receptor modulators, SERMs) were able to enhance the expression of HSPB8, suggesting 
that these steroids may have a protective activity against proteotoxicity induced by misfolded 
proteins. It will be of interest to evaluate whether SERMs, by modulating HSPB8, may exert 
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pharmacological protection against misfolded ARpolyQ and related proteins (Crippa et al. 
Unpublished results). In the same screening we also confirmed that proteasome inhibitors are potent 
inducers of HSPB8 expression, leading us to hypothesize that when the proteasome is overwhelmed, 
and consequently impaired, transcriptional activation of the HSPB8 gene may be triggered in order 
to facilitate the removal of proteins via autophagy (Carra, et al., 2013,Crippa, et al., 2010b,Giorgetti, 
et al., 2014,Rusmini, et al., 2013). Whilst the use of proteasome inhibitors is not appropriate for 
disorders such as SBMA, their effects on HSPB8 can be taken as a proof of principle that proteins 
that accumulate when the proteasome is blocked, may be molecularly re-routed by HSPB8 (in 
complex with BAG3) to the autophagy pathway for clearance. 
 
c) Activation of the UPR response 
 
 
ER stress has been shown to be an early pathological feature of motor neuron disorders, in both the 
SOD1G93A mouse model of ALS and the AR100 model of SBMA (Montague, et al., 2014,Saxena, et 
al., 2009). The effect of pharmacological targeting of ER stress was examined by treatment of 
AR100 SBMA embryonic motor neuron cultures with the ER inhibitor, salubrinal, in order to 
establish whether motor neuron survival was related to the ER stress observed in AR100 motor 
neurons (Montague, et al., 2014). Salubrinal is a selective inhibitor of eIF2α dephosphorylation, and 
consequently diminishes ER stress-mediated apoptosis (Boyce, et al., 2005,Kessel, 2006). 
Treatment with salubrinal improved the survival of cultured motor neurons, in particular AR100 
motor neurons. The expression of activated caspase 12 was significantly higher in AR100 motor 
neurons, but treatment with salubrinal resulted in a marked decrease in expression in AR100 motor 
neurons. Sustained ER stress is known to diminish the ability of the UPR to regulate ER 
homeostasis, resulting in apoptosis. Caspase 12 plays a key role in this ER stress-induced apoptosis 
in mice (Yoneda, et al., 2001). These results therefore show that treatment with an ER stress 
inhibitor prevents activation of the ER-associated cell death pathway in AR100 motor neurons. 
Importantly, inhibition of ER stress in AR100 motor neurons in vitro, by treatment with salubrinal, 
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significantly reduces activation of ER stress-associated apoptosis, by supressing activation of 
caspase 12. Treatment of mutant SOD1 transgenic mice with salubrinal has been shown to delay 
disease progression and attenuate the disease phenotype (Saxena, et al., 2009). ER stress has also 
been implicated in motor neuron degeneration in C.Elegans and Zebrafish models of TDP-43 ALS, 
which is reduced by treatment with salubrinal, resulting in protection against TDP-43 neuronal 
toxicity in vivo (Vaccaro, et al., 2013). In addition, treatment of α-synuclein transgenic mice with 
salubrinal has also been shown to be neuroprotective in mouse model of Parkinson’s disease (Colla, 
et al., 2012a,Colla, et al., 2012b). Thus, pharmacological targeting of the ER stress pathway, one of 
the earliest pathological mechanisms observed in SBMA motor neurons, may be a potential 
therapeutic strategy for SBMA.  
 
d) Targeting other components of the proteostasis network 
 
The proteostasis network is an integrated system of pathways that regulate protein synthesis, 
trafficking and degradation, to ensure proper protein folding and to eliminate misfolded proteins 
when folding repair mechanisms are unsuccessful (Balch, et al., 2008). The overall purpose of this 
network is to maintain the integrity of the proteome in response to environmental or genetic 
stressors. The accumulation of aberrant protein species in SBMA, as in other diseases caused by 
protein misfolding, challenges the proteostasis machinery and at the same time, may accelerate 
aging by interfering with protein folding and clearance and other key cellular processes (Hipp, et al., 
2014). Along with the HSR, other critical components of this network are mediated by nuclear 
factor (erythroid-derived 2)-like 1 (NFE2L1 or Nrf1) and nuclear factor (erythroid-derived 2)-like 2 
(NFE2L2 or Nrf2). Nrf2 controls the antioxidant response by activating the expression of 
antioxidant and detoxification enzymes. Oxidative stress plays a major role in the pathogenesis of 
SBMA (Iida, et al., 2015,Ranganathan and Fischbeck, 2010) and neurodegeneration in general (Lin 
and Beal, 2006). Nrf2 overexpression decreases neuronal loss in a mouse model of amyotrophic 
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lateral sclerosis (Vargas, et al., 2008). The Nrf1 pathway is strongly linked to the antioxidant stress 
response, which has been shown to enhance proteasome activity, thus representing a promising 
target for therapeutic intervention in neurodegenerative diseases (Radhakrishnan, et al., 2010). To 
date, attempts to improve UPS activity to counteract ARpolyQ toxicity in SBMA have been 
unsuccessful. The major challenge is to find compounds that are safe, but capable of inducing 
expression of several components of the proteasome, with the aim of enhancing its activity in cells. 
Paeoniflorin, a major component of Paeonia plants has been shown to be effective in vivo in SBMA 
mice, where it mitigates the behavioural and pathological impairments typical of these model mice 
and induces ARpolyQ clearance via the UPS and autophagy (Tohnai, et al., 2014). The molecular 
mechanism of Paeoniflorin involves upregulation of nuclear factor-YA (NF-YA), a potent inducer 
of the PQC system. The effect of NF-YA is mediated by several molecular chaperones, CHIP and 
TFEB, thus possibly activating a general response to proteotoxic stress, which is able to activate 
both the UPS and autophagy, rather than to promote a focused and selective activity of the UPS.  
 
In the context of the regulation of UPS, HDAC6 modulators have also been shown to exert a 
beneficial role. Their activity is mainly related to the tight functional relationship that exists 
between the UPS and autophagy. Indeed, in a Drosophila model of SBMA, HDAC6 overexpression 
was able to rescue the eye degeneration induced by ARpolyQ as a consequence of a malfunctioning 
UPS (see  (Beitel, et al., 2013) for review). The action of HDAC6 was initially related to its 
potential to activate a compensatory activation of the autophagic pathway (see also below) in 
response to UPS impairment (Pandey, et al., 2007), since HDAC6 also controls autophagosome 
maturation. (J.Y. Lee, et al., 2010). In addition, an enhanced chaperone response may also be 
involved (Hageman, et al., 2010). Importantly, several selective modulators of HDAC6 are now 
available (d'Ydewalle, et al., 2012,Dallavalle, et al., 2012) and may have therapeutic potential in 
SBMA. Efforts in targeting the proteostatic networks and the UPS with small molecules is starting 
to show some promise: using a high-throughput screening, a selective small-molecule inhibitor of 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
the deubiquitinating activity of human USP14 has been recently identified and shown to enhance 
degradation of several proteasome substrates implicated in neurodegenerative diseases (Lee, et al., 
2012,B.H. Lee, et al., 2010). Therefore, small-molecules modulation of the proteostasis network 
represents a promising strategy for the treatment of SBMA and other diseases caused by the 
accumulation of misfolded proteins, as it offers the opportunity to both decrease levels of the toxic 
protein and alleviate its pathogenic effects. 
 
 
Conclusions 
 
Based on the data reported above, SBMA onset and progression may depend on several alterations 
of the pathways composing the intracellular response to proteotoxic stress, known as the PQC 
system. These alterations are associated with the formation of testosterone-inducible misfolded 
species of the ARpolyQ responsible for SBMA, that, by escaping the PQC system, trigger a series 
of downstream cytotoxic events and accumulate in motoneuronal and muscle cells. In the last 
decades, the role of proteostasis in SBMA has been widely studied, not only for the understanding 
of the disease, but also with the aim to find druggable targets to ameliorate disease course. All 
major components of the PQC system are deregulated in SBMA and their functions could be 
potentially rescued with appropriated molecular and pharmacological approaches, already tested 
both on SBMA cell and/or animal models. In particular, the first intracellular response, represented 
by molecular chaperones localized in the cytoplasm or associated with intracellular organelles 
(including ER) can be boosted with commercially available drugs that may be promising for future 
therapeutic approaches. It is possibly the failure or a down-regulation of the chaperones system that 
in SBMA lead initially both to the ARpolyQ intracellular accumulation and to the activation of the 
degradative pathways, the UPR, the UPS and the ALP. Since these three systems work synergically 
and in concert for counteracting the ARpolyQ toxicity, it may be more difficult to act selectively on 
one of these aiming for restoration of the global equilibrium on the PQC system. However, 
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interesting approaches to enhance the functions of the degradative systems have been proposed (in 
particular of the autophagic system) as it has been described in this review. In the perspective of 
future therapeutic approaches, it will be important to deepen the temporal and spatial cross-talk 
between UPS, UPR and ALP for identifying other key molecules involved in the clearance of 
ARpolyQ. 
Although several different therapeutic approaches have already been tested, SBMA is still without a 
cure. Fortunately, among the various effective compounds, here reviewed, most of them able to 
modulate different players able to enhance the PQC system activity in SBMA, it might be worth to 
test the possibility of their combined additive/synergic action. This might allow to tackle different 
steps of the pathways damaged by the ARpolyQ in target cells. The combined approach might 
represent a novel therapeutic perspective and it could be combined even with several active 
compounds targeting other intracellular processes altered in SBMA. 
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Legend to Figure 
 
Fig. 1 Proteostasis regulation in Spinal and Bulbar Muscolar Atrophy (SBMA) 
 
Inactive ARpolyQ is located in the cytoplasm associated with HSPs proteins, in a “non-toxic” 
conformation. Testosterone (T) binding induces the HSPs dissociation unmasking the polyQ tract, 
which is prone to misfold. Misfolded ARpolyQ aggregate in cytoplasm and/or nuclei, An excess of 
misfolded ARpolyQ may alter the intracellular proteostasis. This leads to activation of the 
proteotoxic response mediated by the protein quality control (PQC) system. The PQC comprises: a) 
the chaperones proteins (including the heat shock proteins (HSPs)), the degradative pathways b) 
ubiquitin-proteasome system (UPS), c) autophagy-lysosome pathway (ALP), and d) the unfolded 
protein response (UPR), which activates the endoplasmic reticulum-associated degradation (ERAD).     
Misfolded ARpolyQ is recognized by the HSPs which may assist its refolding or alternatively, 
when  folding cannot be reached, direct it to degradation. The UPR comprises three parallel 
signalling branches: PERK, IRE1α and ATF6 and works with chaperones to determine the fate of 
misfolded proteins. ARpolyQ is mainly refolded by the ATP-dependent HSP70 and HSP40, and 
when this fails is ubiquitinated (by ubiquitin ligases E1, E2, E3) and degraded via UPS and/or ALP. 
HSP70 and HSP40 allow E1-E2-E3 ubiquitination of misfolded ARpolyQ degraded by UPS. 
ARpolyQ ubiquitination is also mediated by the E3-ligase C-terminus of HSC70-interacting protein 
(CHIP) complexed to HSC70 and misfolded ARpolyQ. The fate of this complex is determinated by 
BAG family members acting as HSC70 co-chaperones. BAG1 links HSC70 to UPS through its 
ubiquitin-like (UBL) domain. BAG3 and its partner HSPB8 promote ALP degradation of HSC70 
substrates. BAG3 interacts with the dynein complex moving misfolded ARpolyQ to the 
microtubule-organization center (MTOC) where aggresomes are formed. Alternatively, the histone 
deacetylase 6 (HDAC6) may also interacts with dynein complex, but apparently after CHIP-
mediated ubiquitination of substrates escaping UPS degradation. Polyubiquitinated proteins bound 
to the HSC70-BAGs are recognized by p62/SQSTM1, which interacts with the autophagy marker 
LC3 to allow substrates insertion into autophagosome for degradation. 
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